PL2812351T3 - Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego - Google Patents

Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego

Info

Publication number
PL2812351T3
PL2812351T3 PL13710308T PL13710308T PL2812351T3 PL 2812351 T3 PL2812351 T3 PL 2812351T3 PL 13710308 T PL13710308 T PL 13710308T PL 13710308 T PL13710308 T PL 13710308T PL 2812351 T3 PL2812351 T3 PL 2812351T3
Authority
PL
Poland
Prior art keywords
treatment
pharmaceutical composition
multiple sclerosis
sclerosis
pharmaceutical
Prior art date
Application number
PL13710308T
Other languages
English (en)
Inventor
Krzysztof Selmaj
Marian SZCZEPANIK
Original Assignee
Selmaj
Marian SZCZEPANIK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selmaj, Marian SZCZEPANIK filed Critical Selmaj
Publication of PL2812351T3 publication Critical patent/PL2812351T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13710308T 2012-02-10 2013-02-08 Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego PL2812351T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL398077A PL398077A1 (pl) 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
EP13710308.1A EP2812351B1 (en) 2012-02-10 2013-02-08 Pharmaceutical composition for the treatment of multiple sclerosis
PCT/EP2013/052615 WO2013117742A2 (en) 2012-02-10 2013-02-08 Pharmaceutical composition for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
PL2812351T3 true PL2812351T3 (pl) 2018-09-28

Family

ID=46762685

Family Applications (2)

Application Number Title Priority Date Filing Date
PL398077A PL398077A1 (pl) 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
PL13710308T PL2812351T3 (pl) 2012-02-10 2013-02-08 Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL398077A PL398077A1 (pl) 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego

Country Status (9)

Country Link
US (2) US20150080313A1 (pl)
EP (1) EP2812351B1 (pl)
DK (1) DK2812351T3 (pl)
ES (1) ES2684725T3 (pl)
HU (1) HUE039044T2 (pl)
PL (2) PL398077A1 (pl)
PT (1) PT2812351T (pl)
SI (1) SI2812351T1 (pl)
WO (1) WO2013117742A2 (pl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651328A1 (en) * 2006-05-05 2007-11-15 Opexa Therapeutics T-cell vaccine
DK2240200T3 (en) * 2008-01-25 2016-08-22 Vianex S A THERAPEUTIC MANNA COUPLED myelin basic protein-peptide MBP83-99

Also Published As

Publication number Publication date
DK2812351T3 (en) 2018-07-09
WO2013117742A3 (en) 2014-02-20
PT2812351T (pt) 2018-08-01
HUE039044T2 (hu) 2018-12-28
US20190201484A1 (en) 2019-07-04
EP2812351B1 (en) 2018-03-28
PL398077A1 (pl) 2012-08-27
ES2684725T3 (es) 2018-10-04
EP2812351A2 (en) 2014-12-17
US20150080313A1 (en) 2015-03-19
SI2812351T1 (sl) 2018-11-30
WO2013117742A2 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
LT3378862T (lt) Dihidropirimidinoizochinolinonai ir jų farmacinės kompozicijos, skirti išsėtinės sklerozės gydymui
ZA201407726B (en) Pharmaceutical compositions for combination therapy
SG10201913581UA (en) Pharmaceutical compositions for the treatment of cftr mediated diseases
ZA201505443B (en) Compositions containing phorbol esters for the treatment of stroke
IL240531A0 (en) Pharmaceutical compounds and preparations thereof for the treatment of inflammatory disorders
PL2814473T3 (pl) Kompozycje farmaceutyczne do terapii skojarzonej
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
PL2814462T3 (pl) Kompozycja farmaceutyczna na bazie oleju do leczenia chorób przewodu pokarmowego
SI2812351T1 (sl) Farmacevtski sestavek za zdravljenje multiple skleroze
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
PT2814473T (pt) Composições farmacêuticas para terapia de combinação
AU2011900519A0 (en) Drug compositions for the treatment of insomnia